At the 2025 Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, doctors, scientists, and researchers from around the world shared groundbreaking results pointing to new and promising ways to combat cancer. The event, considered the largest cancer-focused conference globally, was attended by around 44,000 healthcare professionals and featured over 200 scientific sessions centered around this year’s theme: "Driving Knowledge to Action: Building a Better Future." Below is a comprehensive yet concise summary of the most impactful studies and innovations presented.
Leading the developments was immunotherapy, which showed remarkable results in recent trials. One study revealed that the drug pembrolizumab (Keytruda) helped keep head and neck cancer under control for five years compared to just 30 months with traditional treatments. It also significantly reduced the risk of cancer spreading to other parts of the body. In advanced skin cancer cases, a one-time immunotherapy called lifileucel led to tumor shrinkage in most patients, and nearly 1 in 5 survived for five years as an unprecedented outcome for such an aggressive cancer.
A second revolutionary approach highlighted was CAR T-cell therapy, which involves reprogramming a patient’s own white blood cells in the lab to recognize and destroy cancer cells. While previously effective in treating blood cancers, this method now shows promise against solid tumors, which make up about 90% of all cancers, including breast, lung, and pancreatic cancers. A global clinical trial on gastric and gastroesophageal junction cancers showed patients lived on average 40% longer than those receiving standard treatments. In another rare breakthrough, CAR T-cell therapy shrank tumors in 62% of patients with recurrent glioblastoma, a usually fatal brain cancer with limited treatment options as an achievement described as "extraordinary" by researchers.
In the area of early detection, liquid biopsies emerged as a beacon of hope. The UK announced that thousands of cancer patients would soon benefit from a new blood test capable of detecting circulating tumor DNA (ctDNA). This allows for rapid diagnosis and directs patients to treatments tailored specifically to the genetic makeup of their disease ushering in a new era of precision medicine.
The conference also underscored the role of lifestyle in cancer recovery and prevention. A large, randomized clinical trial conducted over more than a decade showed that structured physical activity after treatment reduced the risk of death by 37% and the risk of cancer recurrence or new cancer development by 28%. The researchers called the results “gamechanging,” noting that exercise not only improves survival but also enhances mood, reduces fatigue, and boosts physical strength.
Encouraging developments were also reported for breast cancer, the most common cancer among women. A new drug called camizestrant showed it could block cancer cells from using hormones to grow, delaying the need for chemotherapy and reducing disease progression by 56% compared to standard therapies. In more aggressive and advanced cases, a new triple-therapy approach significantly slowed disease progression and helped patients live longer.
